Brain Cancer Clinical Trials in Pennsylvania

Showing 21-40 of 159 trials

Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas

NCT04869449

This research is being done to find out if the study drug (ketoconazole) can enter brain tumors at a high enough amount to stop the tumor cells from dividing. Ketoconazole is a drug which doctors already use for fungal infections and is thought to be able to effect tumor cells. As treatments for this type of brain tumor are limited, it is hoped that the results of this study will help to determine if the study drug should be studied further as a possible treatment.

GlioblastomaGlioblastoma MultiformeGlioblastoma Multiforme of Brain+1 more

Milton S. Hershey Medical Center1 participantsStarted May 2022

Hershey, Pennsylvania, United States

RECRUITINGPhase 290 miles

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

NCT05188508

This study will test the safety and effectiveness of a combination of pembrolizumab, olaparib, and temozolomide to see how well these drugs work when given together in people with a glioma that either did not respond to previous treatment or came back after treatment.

Glioma

Memorial Sloan Kettering Cancer Center57 participantsStarted Jan 2022

Hartford, Connecticut, United States • Miami, Florida, United States • Basking Ridge, New Jersey, United States +7 more locations

Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

Brain Cancer Trials in Other Cities

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

DAY101 In Gliomas and Other Tumors

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Phase I Study of APX005M in Pediatric Central Nervous System Tumors

Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype

HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma

Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas

Expanded Access to Gallium Maltolate (GaM)

LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

AB154 Combined With AB122 for Recurrent Glioblastoma

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3

[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes

Other Conditions in Pennsylvania